title: Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.
abstract: Strategies for the management of perioperative bleeding in patients with haemophilia and inhibitors have evolved rapidly as a result of the development of the bypassing agents Factor Eight Inhibitor Bypassing Activity, Anti-inhibitor Coagulant Complex (FEIBA) and activated recombinant factor VII (rFVIIa). However, there are currently no established guidelines for perioperative use of bypassing agents, and few controlled clinical studies have been carried out. Thus, case reports, such as those presented here, provide useful anecdotal evidence to guide the treatment of inhibitor patients. The purpose of this report was to describe experiences in the use of bypassing agents in a small cohort of patients with haemophilia A and inhibitors undergoing surgical procedures. Cases from five treatment centres were reviewed. Twenty-two procedures using FEIBA, rFVIIa or a combination of both agents were compiled from seven inhibitor patients (six with an alloantibody inhibitor and one with an acquired autoantibody inhibitor). Eleven procedures used FEIBA monotherapy, two employed rFVIIa monotherapy and nine were performed using combination therapy. Supplemental therapies were required to manage bleeding in some cases. Haemostatic control was achieved in all cases, and treatment regimens were generally well tolerated. One thrombotic adverse event was reported: evidence of disseminated intravascular coagulation (DIC) was found after rFVIIa use in one case, although the direct cause of DIC was unknown. The experiences in this case review demonstrate that both major and minor surgical procedures can be safely performed in patients with haemophilia and high-titre inhibitors under the cover of bypassing agents, with a high expectation of success.
authors: Division of Hematology and Oncology, The Ohio State University, 320 West 10th Avenue, Columbus, OH 43210, USA. Erik.Kraut@osumc.edu
authors: E H
authors: EH
authors: Kraut
authors: L M
authors: LM
authors: Aledort
authors: S
authors: S
authors: Arkin
authors: K C
authors: KC
authors: Stine
authors: W-Y
authors: WY
authors: Wong
mesh_terms: D000328:Adult; D019774:Blood Coagulation Factor Inhibitors / Q000378:metabolism*; D001779:Blood Coagulation Factors / Q000008:administration & dosage* / Q000009:adverse effects; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005167:Factor VII / Q000008:administration & dosage* / Q000009:adverse effects; D015942:Factor VIIa; D005260:Female; D006467:Hemophilia A / Q000150:complications* / Q000276:immunology; D006801:Humans; D007223:Infant; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa